Health and Fitness Health and Fitness
Tue, February 15, 2011
Mon, February 14, 2011
Fri, February 11, 2011
Thu, February 10, 2011
Wed, February 9, 2011
Tue, February 8, 2011
Mon, February 7, 2011
[ Mon, Feb 07th 2011 ] - Market Wire
00 A.M. EST
Sun, February 6, 2011
Fri, February 4, 2011
Thu, February 3, 2011
Wed, February 2, 2011
Tue, February 1, 2011
Mon, January 31, 2011
Sun, January 30, 2011
Fri, January 28, 2011
Thu, January 27, 2011

Teva Invites Public to Listen to Its 2011 Investor Meeting Webcast


//health-fitness.news-articles.net/content/2011/ .. listen-to-its-2011-investor-meeting-webcast.html
Published in Health and Fitness on Tuesday, February 8th 2011 at 3:20 GMT by Market Wire   Print publication without navigation


JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) invites investors and the general public to listen to a live audio webcast of its 2011 Investor Meeting on Wednesday, February 9, 2011 at 3:00 p.m. ET.

What:

Tevaa™s 2011 Investor Meeting

Who:

Teva Management

When:

Wednesday, February 9, 2011 at 3:00 p.m. ET

Where:

[ www.tevapharm.com/financial/ ] or

[ http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=73925&eventID=3720181 ]

How:

Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before).An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $13.9 billion in net sales in 2009.


Publication Contributing Sources